We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Renal Cell Carcinoma

Expert Opinion / Cases · May 03, 2017

Widely Metastatic ccRCC in 40-Year-Old Female

Written by
Heather R Greene MSN, FNP, AOCNP


Additional Info

Disclosure statements are available on the authors' profiles:

Discuss This item Follow

No comments yet, be the first to start the discussion!

  • rebaz haji

    use temsirolimus because poor risk category

  • Huan Wang

    Considering type of histology is ccRCC. So I believe sunitinib or pazopanib is first-line treatment choice for the patient.

  • Jan 25, 2021

    Pending Moderator approval.

Further Reading